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Abstract
Major mood disorders have been linked to abnormalities in circadian rhythms, leading to disturbances in sleep, mood,
temperature, and hormonal levels. We provide evidence that ketamine, a drug with rapid antidepressant effects, influences
the function of the circadian molecular machinery. Ketamine modulates CLOCK:BMAL1-mediated transcriptional activation
when these regulators are ectopically expressed in NG108-15 neuronal cells. Inhibition occurs in a dose-dependent manner
and is attenuated after treatment with the GSK3b antagonist SB21673. We analyzed the effect of ketamine on circadian
gene expression and observed a dose-dependent reduction in the amplitude of circadian transcription of the Bmal1, Per2,
and Cry1 genes. Finally, chromatin-immunoprecipitation analyses revealed that ketamine altered the recruitment of the
CLOCK:BMAL1 complex on circadian promoters in a time-dependent manner. Our results reveal a yet unsuspected
molecular mode of action of ketamine and thereby may suggest possible pharmacological antidepressant strategies.
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Introduction
Major depressive disorder (MDD) is a serious and recurrent
psychiatric illness with a prevalence rate of 6.7% in the United
States in any 12 month period [1,2]. Currently available
monoaminergic antidepressant drugs require weeks to months
for a full clinical response [3] during which time patients may be at
risk for suicidal behavior [4]. Furthermore, a significant number of
patients fail to respond to currently available antidepressant
medications [5,6]. There is a growing interest in glutamatergic-
based therapeutics as an alternative treatment to conventional
antidepressants. Ketamine, a non-competitive high affinity
NMDA (N-methyl-D-aspartate) glutamate receptor antagonist,
has rapid and robust antidepressant actions in animal models of
depression when administered intravenously in low subanaesthetic
doses [7].
Clinical studies of low-dose intravenous ketamine report
improvement within 24 hours (for review see [8]). An estimated
70% of MDD patients respond to ketamine [9,10]. Approxi-
mately 35% of responders have sustained improvement up to 7
days after a single dose [10,11] or longer after repeated doses
[12,13].
Accumulating evidence suggests that ketamine alters circadian
rhythms, which may be linked to its rapid antidepressant action.
Ketamine dampens phase-shifting responses to light [14] and
alters diurnal rhythms of the widespread NMDA and AMPA
receptors in the SCN. Activation of glutamate receptors increases
the mRNA levels of the core clock genes Per1 and Per2 [15,16].
Also, ketamine inhibits the photic induction of Fos-like immuno-
reactivity in the suprachiasmatic nucleus (SCN) (the central
regulator of circadian rhythms in mammals) [17]. Both AMPA
[18] and NMDA [19] show 24 hour rhythms in the SCN in
rodents. Further, the hypnotic efficacy of ketamine increases
during the early active phase in mice (11pm) as compared to the
early inactive phase (10am) [20]. In humans, ketamine has
chronopharmacological properties with maximum anesthetic
effects at night [21].
Dysregulation of the circadian system has been linked to
depressive disorders. Circadian abnormalities in mood, sleep,
temperature, and neuroendocrine function are associated with
depression in a subgroup of patients [22,23]. Diurnal patterns of
mood can persist for many months through the course of a
depressive episode. Typically, a subgroup of depressed patients will
awaken with a severe psychotic depression in the early morning
which decreases to an almost euthymic state by evening [24,25].
Approximately 70–80% of depressed patients report difficulties in
sleep ranging from initiating and maintaining sleep to early
morning awakening and restlessness [26]. Thermoregulatory
deficits associated with depression include elevated nocturnal core
body temperature [27,28]. Disturbances in the hypothalamic-
pituitary-adrenal (HPA) axis [29], reflected by alterations in CRH
and cortisol levels, are frequently associated with depression
[23,30]. Circadian alterations in depressed patients are variable
and can range from phase advances, phase delays, or changes in
amplitude. However, consistent abnormalities are the phase
advances of physiological events including the shortening of the
latency of the first rapid eye movement (REM) stage, early
awakening and an early peak of adrenocorticotrophic secretions
[23,27,30].
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which include three period (encoding the proteins PER1, PER2
and PER3), two cryptochrome (encoding CRY and CRY2), two
Bmal (encoding BMAL1 and BMAL2) and two Clock (encoding
CLOCK and NPAS2) genes. These critical components of the
mammalian clock machinery operate as transcriptional regulators
organized in interlocked transcriptional and post-translational
feedback loops. A major feedback loop involves CLOCK and
BMAL1 which act as a heterodimer to rhythmically drive the
transcription of Per and Cry genes. The PER and CRY proteins
accumulate and dimerize in the cytoplasm, then translocate into
the nucleus where they bind to CLOCK:BMAL1 to inhibit their
own transcription. Importantly, this regulatory system controls
also the expression of many clock-controlled genes (CCGs)
through promoter elements called E-boxes located in their
regulatory regions. Since about 10–15% of all cellular transcripts
are controlled by the clock [31], it is obvious that CCGs are
involved in a large array of biological functions, including the
control of several physiological functions, like aging [32–36] and
cellular metabolism [37,38]. Finally, the cyclic control of a large
fraction of the genome implicates global changes in chromatin
remodeling [31]. A key discovery towards the understanding of
how the circadian machinery may participate in chromatin
remodeling demonstrated that CLOCK also possesses intrinsic
histone acetyltransferase (HAT) activity [39,40] that regulates
circadian expression through direct chromatin remodeling.
A question to be addressed relates to how the activation of
intracellular signaling pathways is integrated at the level of the
circadian transcriptional machinery. Environmental cues, primar-
ily light, can reset the daily phase of internal molecular rhythms.
Light signals are transmitted from the retina via the retinohy-
pothalamic tract (RHT) to the SCN. The RHT neurons release
glutamate in the ventrolateral SCN. Activation of the NMDA
receptor initiates a cascade of events leading ultimately to the
induction of immediate-early genes and clock genes [41,42]. The
potential significance of these complex interactions is that
ketamine may act at specific sites within the circadian transcrip-
tional machinery to promote circadian phase shifts, although thus
far there is no direct evidence of this.
Recent work has implicated the mammalian target of
rapamycin (mTOR) as a potential site for ketamine’s rapid
antidepressant actions. When mTOR is blocked, ketamine’s
antidepressant effects in animal models of depression are abolished
[43]. Other actions of mTOR include the attenuation of phase-
delaying responses to early night-light in the SCN. Blocking
mTOR significantly dampens the light-induced expression of the
circadian PER1 and PER2 proteins [44,45].
The aim of this study was to investigate ketamine’s effects on
circadian gene expression. We demonstrate that ketamine acts by
modulating the activation potential of the CLOCK:BMAL1
complex by interfering with their recruitment to chromatin at a
target circadian promoter. Our results reveal a yet unsuspected
molecular mode of action of ketamine and thereby suggest possible
pharmacological antidepressant strategies.
Results
Ketamine inhibits CLOCK:BMAL1 transactivation
potential
To explore the effect of ketamine on circadian physiology we
decided to monitor how it may influence clock gene expression. To
do so, we analyzed whether ketamine could modulate CLOCK:
BMAL1-driven transcription. A reporter constituted by the mPer1
gene promoter fused with the luciferase gene was ectopically
expressed in NG108-15 neuronal cells by transient transfection. As
previously reported [46], co-expression of CLOCK:BMAL1
results in activation of the mPer1 promoter. The effect of ketamine
was analyzed by treating the transfected cells with increasing doses
of ketamine. While ketamine has no effect on the basal mPer1
promoter activity, it significantly induced a dose-dependent
reduction of CLOCK:BMAL1-driven activation (Fig. 1A).
Since the activity of the mPer1 promoter has been shown to be
influenced by signaling pathways which utilize transcription
factors other than CLOCK:BMAL1 [42,47,48], we sought to
investigate whether the effect of ketamine is mediated uniquely by
the E-box elements. We transfected a reporter containing three
consensus E-box sequences located upstream of the luciferase
gene. Importantly, ketamine significantly affected CLOCK:
BMAL1-driven transcription by acting on the E boxes. This effect
was abolished when the E-boxes were mutated to impair
CLOCK:BMAL1 binding (Fig. 1B). Thus, the effect of ketamine
is specifically directed on the CLOCK:BMAL1 complex.
The effect of ketamine appears to be dose-dependent. While the
doses used in the in vitro experiments are obviously higher than
that used in human antidepressant studies, they are comparable to
other studies in various neuronal and not neuronal cell types [49–
53].
To better understand the molecular mechanisms implicated in
the effect of ketamine on CLOCK:BMAL1-driven transcription,
we treated transfected NG108-15 cells with various protein kinase
inhibitors in the presence or absence of ketamine. Interestingly,
the ketamine-induced repression of CLOCK:BMAL1 is reduced
after treatment with the GSK3b inhibitor, SB216763, while it
remains unaltered after treatment with the mitogen-activated
protein (MAP) kinase kinase MEK1/2-specific inhibitor, UO126
or the PKC inhibitor, GF109203 (Fig. 1C). This data suggests that
the inhibitory effect of ketamine on circadian function involves
GSK3b, a kinase that has been already implicated in the
regulation of various circadian proteins [54–58] and which has
been linked to the regulation of depressive disorders [59,60].
Ketamine alters circadian gene expression
The finding that ketamine treatment inhibits the transcriptional
potential of CLOCK:BMAL1 prompted us to investigate how this
effect might influence circadian gene expression. Circadian
transcription can be readily studied in mouse embryonic
fibroblasts (MEFs), which are synchronized in response to a
2 hrs exposure to 50% horse serum. MEFs generated from wild-
type mice were thereby treated with ketamine at various times
after serum-induced synchronization. RNA was extracted from
cells arrested at various times after the serum-shock and analyzed
using quantitative PCR. The analysis revealed that ketamine alters
the expression of clock genes (Bmal1, Per2,C ry1) and of the clock-
controlled Dbp gene during the circadian cycle. Remarkably, Per2,
Cry1 and Dbp gene expression showed a dose-dependent reduction
of the amplitude of the oscillation while Bmal1 and Dbp expression
appeared to be phase-shifted (high dose ketamine) (Fig. 2). Thus,
the influence of ketamine on CLOCK:BMAL1 (Fig. 1) is
paralleled by a significant effect on the circadian expression of
endogenously oscillating genes.
Chromatin recruitment of CLOCK:BMAL1 to circadian
promoters is affected by ketamine
Based on the significant effect of ketamine on circadian
transcription, we sought to decipher the mechanism by which
ketamine exerts its action. As ketamine appears to act directly on
CLOCK:BMAL1 (Fig. 1) and does not affect the stability of
CLOCK and BMAL1 proteins (not shown), we reasoned that
Effect of Ketamine on the Circadian Clock
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tin. Thus, we tested CLOCK:BMAL1 recruitment by dual cross-
linking chromatin immunoprecipitation (ChIP) assays on the
regulatory region of the Dbp clock-controlled gene (Fig. 3a). ChIPs
were performed on MEFs after serum shock synchronization and
ketamine treatment, and analyzing the E-box in the Dbp UP
region, previously validated to bind CLOCK:BMAL1 [61]. As
expected, CLOCK and BMAL1 were both recruited in a time-
dependent manner to this region. Importantly, ketamine reduced
the recruitment of both CLOCK:BMAL1 at CT24, which
parallels the decrease in gene expression observed in response to
ketamine (Fig. 3A). No recruitment was observed at the 39 UTR
region of the same promoter (Fig. 3B). This result constitutes the
first case of a pharmacological treatment that alters the
recruitment of the circadian machinery to a target promoter.
These results confirm that ketamine operates on circadian gene
expression by directly modulating some key components of the
circadian machinery.
Discussion
The data from this study indicate that ketamine alters circadian
rhythms through the inhibition of CLOCK:BMAL1 mediated
transcription. The effect on transcriptional activation is paralleled
by the effect on circadian gene expression in cultured cells: we
found time-dependent changes in clock gene expression by
Figure 1. Ketamine treatment represses CLOCK:BMAL1 transactivation potential on the mPer1 gene promoter. (A) Effect of ketamine
on CLOCK:BMAL1 dependent transcription. Vectors expressing CLOCK:BMAL1 (C:B, 25 ng each) were cotransfected with a construct containing the
mPer1 promoter (pGL3-mPer1-Luc, 50 ng) in NG108-15 cells. The total DNA amount was kept constant by adding carrier plasmid DNA. After 6 hs of
transfection, cells were treated with increasing amounts of ketamine (K, 18 h, + as 10 mM and ++ as 1 mM). After normalization for transfection
efficiency using b-galactosidase activity, reporter gene activities were expressed relative to those of a control transfected only with non-expressing
plasmids. All the values are the mean +/2 SD (n=3); (**) p,0.01. (B) The E box promoter element mediates ketamine repression of CLOCK:BMAL1.
Experimental conditions were as in A except that reporter constructs containing three copies of the E box consensus sequence (pGL3 promoter (E
box) X3 LUC) or its mutated form (pGL3 promoter (Emut) X3 LUC) were used. All values are the mean +/2 SD (n=3); (*) p,0.05, (**) p,0.01. (C)
Ketamine repression of CLOCK:BMAL1 involves activation of GSK3b. Experimental conditions were as in B except that the kinase inhibitors UO126
(ERK kinase inhibitor), SB216763 (GSK3b kinase inhibitor) and GF109203 (PKC kinase inhibitor) were applied to cells together with ketamine treatment
(K, ++ as 1 mM). % of repression of CLOCK:BMAL1 transactivation with ketamine alone or ketamine with different kinase inhibitors is shown. All values
are the mean +/2 SD (n=3); (*) p,0.05.
doi:10.1371/journal.pone.0023982.g001
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observed on clock genes with different phases of oscillation.
Antiphase oscillations in Bmal1 and Dbp expression have been
described previously in MEFs [62]. As can be seen in figure 2, our
control data confirmed these findings as both Bmal1 and Dbp were
expressed antiphasically. A dampening of Per2 mRNA oscillation
at both ketamine doses was seen at CT18 post serum shock, lasting
for a total of 12 hours before returning to normal levels. No phase
shifts were seen in Per2 mRNA levels over the course of 30 hours.
In contrast, low and high doses of ketamine appeared to disrupt
Cry1 oscillations to produce a reduction in amplitude. Although
statistically not significant, we have observed a trend in which high
doses of ketamine produced a gradual rise in Cry1 mRNA levels,
which persisted throughout the cycle. Low doses of ketamine are
instead associated with a sharper rise in Cry1 levels at CT 24,
suggesting a possible trend toward phase delay. Importantly, the
effects on circadian expression elicited by short-lasting treatments
(1 hour) are reminiscent of the consequences of ketamine
treatment in vivo.
Additional in vitro and in vivo studies using neuronal cell lines
and neuronal tissues from mice treated with ketamine at different
times of the circadian cycle will help further our understanding.
We also elucidated the pathways that are primarily involved in
ketamine’s effect by blocking kinases that play a role in the
transmission of intracellular signals. We observed that the specific
blocking of the Akt/GSK3b pathway reduced the effect of
ketamine on the circadian system. This initial observation is of
interest for future investigations in this direction. Furthermore,
while treatment with other kinase inhibitors had no apparent effect
on ketamine under the experimental conditions used, we cannot
exclude that other pathways could be activated during treatment
with ketamine [63]. Future in vivo experiments will help clarify
these mechanisms.
To our knowledge this is the first study to demonstrate
ketamine’s effects on the core clock genes and could suggest an
additional mechanism of action underlying clinical and preclinical
observations of ketamine-induced rapid antidepressant actions.
Although several actions of ketamine have been described,
including effects on synaptic plasticity, AMPARs, NMDARs,
and most recently on mTOR, to our knowledge no studies have
investigated the possible interaction of ketamine with the circadian
system.
Circadian rhythm abnormalities have long been associated with
the pathophysiology of depressive illness. Shifting circadian
rhythms using non-invasive interventions such as bright light,
sleep phase advance, and/or sleep deprivation therapies induce
rapid improvement in a subgroup of patients. It is hypothesized
that these treatments act by resetting abnormal circadian rhythms
[8,22,23]. Drug interventions including antidepressants and mood
stabilizers may accomplish this by synchronizing clock gene
Figure 2. Altered circadian expression of clock genes and CCGs after ketamine treatment. Per2, Dbp, Bmal1 and Cry1 mRNA expression
profiles in WT MEFs, untreated or treated for 1 h with ketamine (10 mM and 1 mM) at circadian times CT11–12, CT17–18, CT 23–24, CT29–30 after
serum shock, were analyzed by quantitative PCR. The values are relative to those of 18S mRNA levels at each CT (circadian time). Time 12 (CT12) value
in untreated cells was set to 1. All values are the mean +/2 SD (n=3); (*) p,0.05, (**) p,0.01, (***) p,0.001.
doi:10.1371/journal.pone.0023982.g002
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and is thought to act by inhibiting GSK3b [55,65]. GSK3b
phosphorylates various clock proteins, affecting their stability to
modulate the negative feedback loop to CLOCK:BMAL1
[54,56,57]. Importantly, we have reported here that the action
of ketamine appears to be specifically blocked by a GSK3b
inhibitor (Fig. 1). This is consistent with data showing that
inhibition of GSK3b is necessary to ketamine’s rapid antidepres-
sant action in a mouse model of depression (learned helplessness)
[66].
Data from mammals suggest that 2–3 hours are required post-
phase shifts to reset behavioral rhythms [67]. This effect was
demonstrated in cultured SCN cells using real-time imaging data
from transgenic mice carrying a luciferase reporter gene. NMDA
applied to the SCN either induced phase delays at peak oscillation
times or phase-advances during the trough phase of luminescence
demonstrating that the direction and magnitude of the NMDA-
induced phase shifts are dependent on the circadian phase [67].
While we have not addressed whether the effect of ketamine on
circadian gene expression is mediated by NMDA, it is important
to underscore that NMDA receptors are expressed in different
types of non-neuronal cells [68–72]. Future studies will help to
better elucidate the mechanisms of action of ketamine on the
circadian system in neuronal and non-neuronal tissues. As Clock
mutant mice display manic-like behaviors, which can be reversed
by lithium [73], it will of interest to explore how ketamine
influences circadian behavior. Our findings favor a scenario in
which these rapid changes in circadian clock gene expression may,
in part, play a role in the rapid antidepressant actions associated
with ketamine.
Materials and Methods
Reagents and plasmids
Ketamine-HCl, UO126, SB216763, GF109203 were purchased
from Sigma. Plasmids expressing myc-tagged mClock and FLAG-
myc-tagged mBmal1 were described previously [74]. Plasmids
expressing both b-galactosidase (pGL3-lacZ) for transfection
control, and luciferase (luc) for luminometry based expression,
pGL3-mPer1-Luc promoter, pGL3-Ebox X3-luc, and pGL3-Emut
X3-luc, were described previously [47].
Antibodies
Antibodies against CLOCK and rabbit IgG were from Santa
Cruz Biotechnology, antibody against BMAL1 was described
earlier [40].
Cell culture
NG108-15 cells were grown in DMEM (4.5 g/L glucose)
supplemented with heat-inactivated 10% fetal bovine serum (FBS)
Figure 3. Altered CLOCK and BMAL1 circadian recruitment to CCGs promoter after ketamine treatment. Cross-linked cell extracts were
isolated at the indicated time points after serum shock from MEFs, not treated or treated with ketamine (1 mM) for 1 h before each time point. The
samples were subjected to ChIP assay with anti-CLOCK, anti-BMAL1 and anti-IgG, and analyzed by quantitative PCR with primers for Dbp promoter.
Control IgG (ctr) and Dbp 39UTR (39 region of Dbp promoter) primers were used as controls for immunoprecipitation and PCR, respectively. All the
values are the mean +/2 SD (n=3); (*) p,0.05, (***) p,0.001.
doi:10.1371/journal.pone.0023982.g003
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generated from wild type C57BL/J mice and cultured in DMEM
(4.5 g/L glucose) supplemented with 10% FBS and antibiotics.
Transient transfection and luciferase assay
Cells were transfected with BioT (Bioland) according to the
manufacturer’s protocol. Cell extracts were subjected to a
luminometry-based luciferase assay and luciferase activity was
normalized by b-galactosidase activity.
Quantitative RT-PCR
Each quantitative real-time RT-PCR was performer using the
Chromo4 real time detection system (BIO-RAD). The PCR
primers for murine Per2, Cry1, Dbp, Bmal1 mRNA, 18S rRNA,
Dbp UP promoter region, Dbp 39 UTR promoter region were
described previously (61). For a 20 ml PCR, 25 – 50 ng of cDNA
template was mixed with the primers to final concentration of
300 nM and 10 ml of iQ SYBR Green Supermix (Bio-Rad),
respectively. The reaction was first incubated at 95uC for 3 min,
followed by 40 cycles at 95uC for 30 s and 60uC for 1 min.
Chromatin Immunoprecipitation (ChIP) assays
Dual cross-linking ChIP assay [75] was used. Briefly, after 2 h of
serum shock with media containing 50% horse serum, cells were
incubated with serum-free medium for the indicated time.
Ketamine treatment was added 1 h before the collection. Then,
cells were washed three times with room temperature PBS and
PBS with 1 mM MgCl2 was added. Disuccinimidyl Glutarate
(DSG, Pierce) was added to a final concentration of 2 mM for
crosslinking and incubated 45 min at room temperature, formal-
dehyde was added to a final concentration of 1% (v/v) and cells
incubated for 15 min for dual crosslinking, and glycine was added
to a final concentration of 0.1 M and incubated for 10 min to
quench formaldehyde cross-linking. After harvesting, cells were
lysed in 500 mL ice-cold cell lysis buffer (50 mM Tris/HCl
pH 8.0, 85 mM KCl, 0.5% NP40, 1 mM PMSF, 1x protease
inhibitor cocktail (Roche)) for 10 min on ice. Nuclei were
precipitated by centrifugation (3000 g for 5 min), resuspended in
600 mL ice-cold RIPA buffer (50 mM Tris/HCl pH 8.0, 150 mM
NaCl, 1 mM EDTA pH 8.0, 1% Triton X-100, 0.1% SDS, 0.1%
sodium deoxycolate, 1 mM PMSF, 1x protease inhibitor cocktail)
and incubated on ice for 30 min. Sonication was performed to
obtain DNA fragments 100–600 bp in length.
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